Immunotherapy Special Issue 2019

An early clinical trial participant likens his journey into the unknown to a space mission.

A man who received chimeric antigen receptor-T cell therapy shares his firsthand account.

Although there is much to learn about the intricacies of how the immune system interacts with cancer, advances are occurring rapidly as immunotherapy for cancer has exploded with myriad ongoing clinical trials and newer drugs coming on line constantly.

In this special issue of CURE®, we take a walk through history, from revisiting the major medical milestones of immunotherapy to reviewing how far it has come in cancer treatment.

Immunotherapy medications have been a wonderful addition to the arsenal of cancer therapeutics. Their use has revolutionized the treatment of many cancers and offers new hope to patients. However, these upsides do not come without downsides.

Treatment with Opdivo (nivolumab) plus Yervoy (ipilimumab) led to a 44% response rate in patients with high-grade neuroendocrine tumors, according to phase 2 study findings.

Cutting-edge treatment is not out of reach, thanks to a little guidance from the Cancer Research Institute.

A look back at how immunotherapy began in oncology.

For some patients with melanoma, eating a diet rich in fiber could lead to an improved response to immunotherapy, according to findings presented at this year’s American Association for Cancer Research annual meeting.

As immunotherapies emerge in the treatment of liver cancer, experts examine whether two or more is better than one.

Immunotherapy takes on a new role in treating patients with triple-negative disease.